Thermo Fisher Scientific Opens Doe & Ingalls Northeast cGMP Chemical Distribution Facility
Thermo Fisher Scientific Inc. has announced the opening of its new Doe & Ingalls Northeast cGMP chemical distribution facility to meet the growing demand for quality compliance, production chemical storage and supply chain services for the biopharmaceutical, life science and advanced technology markets.
“A secure, robust supply chain is crucial for manufacturers to remain competitive, reduce total cost of ownership and mitigate risk of supply interruption,” said Jeff Jochims, president, research and safety markets, Thermo Fisher Scientific. “Our new Doe & Ingalls facility offers customers the ability to ramp up or expand their production capabilities quickly and cost-efficiently. By leveraging our scale and depth of capabilities in production materials supply chain, our customers can focus their internal resources on what they do best — developing new pharmaceuticals and technologies.”
Located in Peabody, Mass., the 56,000 sq ft, state-of-the-art facility is designed to protect raw material integrity, control the flow of goods and deliver supply chain services. The facility is cGMP-compliant to assure products and processes are in strict compliance with regulatory agencies and meet and/or exceed standards for temperature control, audit log/documentation and product handling/sampling. Innovative supply chain services include
• Storage and warehousing of chemical and raw materials
• Dip tube exchange and temperature-controlled 2-8°C cold storage
• ISO Class 8 and Class 100 cleanrooms provide sampling services for sourcing and quality control (QC) testing of production chemical materials.
“We welcome and celebrate this expansion,” said Massachusetts Governor Deval Patrick. “This facility underscores Thermo Fisher’s commitment to the leading life sciences supercluster in the world.”
“We congratulate Thermo Fisher on the opening of the Doe & Ingalls site,” said Robert K. Coughlin, president and chief executive officer of MassBio, a life sciences trade organization. “This site will be an excellent resource for our members, many of whom are challenged to operate as a GMP-compliant operation when it’s time to scale up to pilot manufacturing. This facility will provide critical services to get them up and running, shortening the time it takes to get new products to market and to the patients who need them.”
Related News
-
News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel
A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to... -
News Protecting life-saving therapies: CPHI Online Podcast Series
The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.
-
News 2026 Outsourcing Outlook Update - pharma at a crossroads
The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ... -
News Roche maintains German investment commitment whilst rivals scale back
Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.
-
News Women in Pharma: The History of CPHI Women in Japan
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News EU drafts deal to end essential medicines shortage
European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.
-
News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg
The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th... -
News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026
CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.